Exjade: improved bioavailability for new presentation

Exjade (deferasirox) is now available as a film-coated tablet, a strength-adjusted formulation of deferasirox with higher bioavailability than Exjade dispersible tablets.

As a result of its improved bioavailability the dose for the film-coated tablet is 30% lower than that of the dispersible tablet. Accordingly, the film-coated tablet is available in lower strengths than the dispersible tablet (90mg, 180mg and 360mg versus 125mg, 250mg and 500mg, respectively).

As a risk mitigation measure to avoid medication errors, and in agreement with the European Medicines Agency, Novartis plans to discontinue Exjade dispersible tablets in the UK at the end of June 2017.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

First COVID-19 vaccine approved for use in the UK from next week

First COVID-19 vaccine approved for use in the UK from next week

The MHRA has approved the COVID-19 vaccine developed...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

SGLT2 inhibitors summarised in new MIMS table

SGLT2 inhibitors summarised in new MIMS table

Prescribers can quickly compare key features and benefits...